Clarus is an Illinois-based pharmaceutical company that develops and commercializes novel therapeutics for the treatment of hypogonadism... Read more
Clarus is an Illinois-based pharmaceutical company that develops and commercializes novel therapeutics for the treatment of hypogonadism... Read more
News
Oct 28, 2022
Markets Insider
Clarus Therapeutics: Tolmar Announces Acquisition of JATENZO (testosterone undecanoate) for the Treatment of Hypogonadism to Expand its Market Leading Urology Portfolio
Oct 19, 2022
Daily Herald
Clarus: Buffalo Grove company buys Clarus Therapeutics drug
Oct 18, 2022
MarketScreener
Clarus: Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO and Selection of Tolmar, Inc. as Successful Bidder
Sep 06, 2022
MarketScreener
Clarus: Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code
Aug 19, 2022
Owler
Clarus Therapeutics, Inc.: Clarus's revenue changed from $15.64M in Mar 2022 to $16.91M in Jun 2022
Aug 18, 2022
BioSpace
Clarus: Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction
Jul 24, 2022
MarketScreener
Clarus: Certain Warrants of Clarus Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 24-JUL-2022.
Jun 09, 2022
StreetInsider
Press Release: Clarus : Clarus Therapeutics to Present New Data for JATENZO (testosterone undecanoate) at ENDO 2022, the Endocrine Society's Annual Meeting
May 18, 2022
FirstWord Pharma
Clarus: Clarus Therapeutics Announces Issuance of Patent Covering JATENZO (testosterone undecanoate)
May 17, 2022
Owler
Clarus Therapeutics, Inc.: Clarus's revenue changed from 13.96M in Dec 2021 to 15.64M in Mar 2022
Clarus Therapeutics Competitors
1
2
3
4
5
6
7
8
9
10